Endocrine Abstracts

Background: Antithyroid drugs (ATDs) are the first line treatment for Graves’ disease in Europe and Asia. However, their long term-efficacy is doubtful, with a high disease relapse rate after discontinuation. Radioiodine and surgery can be used as a second line therapy as definitive approaches after ATDs failure. In recent years, the GREAT and the CSS scores have been suggested to assess the risk of relapse at the time of disease onset, but no data are available about th...

Introduction: Differentiated thyroid cancers (DTCs) carrying BRAF and TERT mutations are associated with high-risk clinicopathological features and poor prognosis. However, there are currently no studies comparing BRAF-TERT tumors to other double mutated DTCs.Aim: To verify whether BRAF-TERT mutated DTCs differ from other double mutated DTCs in terms of clinicopathological characteristics and outcome.Materials and Methods: 168 DTCs...

Introduction: There is no clear indication for radioiodine treatment (RAI) in patients affected by differentiated thyroid cancer (DTC) in Stage I and ATA intermediate risk, according to American Thyroid Association (ATA) guidelines.Purpose: Our aim is to evaluate whether integration of BRAF status and thyroglobulin TSH-stimulated at the time of RAI (A-HTg) could further improve accuracy of stratification, and therefore therapeutic management, in DTC pati...

Introduction: Although 18F-FDG-PET has found wide application in the management of radio-refractory differentiated thyroid cancers (RAI-R-DTCs), alternative radiotracers, including 68Ga-PSMA have been recently evaluated. Prostate-specific membrane antigen (PSMA) is in fact overexpressed in the microvasculature of several solid malignancies including thyroid cancers.Aim: To compare the diagnostic performance between 68Ga-P...